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 Treatment with interferon (IFN) for renal cell carcinoma 
was started in 1982 as one of the immunotherapies, but it is 
not so effective and no definite way of administration has 
been established yet. In thie report for the purpose of study-
ing　 the　 action　 mechanism　 of　 IFN-α and　 IFN-γ, cytotoxic
activity of peripheral blood mononuclear cells (PBMNCs) of 
the patients with renal cell carcinoma. 
 When the patients' PBMNCs were treated with IFNs at 
various concentrations, difference was noted in each patient 
referring to IFNs and their concentrations for obtaining the 
maximum LAK-like activity using ACHN derived from 
human renal cell carcinoma as target cells. Further, the
combined　 effect　 of　 cytotoxicity　 obtained　 by　 IFN-α and　 IFN-
γ at　their　 optimal　 concentration　 was　 additive　 in　 comparison
with　 LAK-like　 activities　 upon　 therapy　 with　 IFN-α or　 IFN-
γ alone　 respectivly.　 Further,　 when　 the　 action　 mechanism　 of
IFN-γ was　 studied　 referring　 to　 subpopulation　 of　the　 normal
donor'PBMNCs　 by　 cell　 sorting,　 the　 strong　 LAK-like　 activity
was　 induced　 on　 the　 lymphocyte　 fraction　 CD3(+)CD4(-).
Further　 in　 consideration　 of　 cytokine　 concentrations　 meas-
ured　 and　 the　 above　 results,　 it　seems　 that　 IFN-γ acts　 directly
on the lymphocyte fraction CD3(+) CD4(-) to induce the 
LAK-like activity.
INTRODUCTION 
 Metastasis to distant organs is the principal cause of 
death from renal cell carcinoma. No commonly accepted 
therapy is available for renal cell carcinoma with metasta-
sis. However, it is suggested that interferon (IFN) can 
influence the natural course of the disease. Since 1982 when 
IFN was firstly used for renal cell carcinoma, the results 
of clinical studies investigating single agent IFN- a sug-
gest that this induces objective resonse in about 20W") of 
the patinets with renal cell carcinoma; IFN- r is associ-
ated with a 20-33% 61--91 response rate among these patinets. 
In recent years as one of trials in the combination therapy 
with various biological response modifiers (BRM), the 
combination of IFN- a and IFN- r was successful, with an 
objective response rate of 15-50% lo)-14) We studied on 
immunological changes and action mechanism in the 
patients with renal cell carcinoma under the combination 
therapy with IFN- a and IFN- r .
MATERIAL AND METHOD 
Patients 
From September 1989 to September 1993, nine patients 
with reanl cell carcinoma were treated with natural inter 
f eron- a (nIFN- a) and recombinant interferon- r (rIFN- r). 
Five patients were male and four were female. Their age 
ranged from 56 to 74 (mean 68.4) years. Three patients had 
undergone nephrectomy and six patients had progressive 
metastasis of renal cell carcinoma. The tumor were staged 
as described by Robson. One patient had stage 1, two had 
stage 2, and six had stage 4. None had received any 
cytotoxic or immunomodulatory antitumor therapy 
during IFN treatment. 
Theraputic Protocol 
Patients had been treated with combination therapy of 
nIFN- a (HLBI, Sumitomo Chemical Industries, LTD., 
Osaka, Japan) and rIFN- r (OH-6000; Othuka Farma-
ceutica, Co. Ltd., Tokusima, Japan) for 1 to several weeks. 
The nIFN- a was given intramuscular injection (dose:3 X 
106 international units (IU)) every day and nIFN- r was 
given as continuos subcutaneous injection for 12 hours 
(dose: 3 X 106 IU) every day. The nIFN- a was started at 
first and rIFN- r was added 7 days later. 
Isolation of peripheral blood mononuclear cells 
Peripheral blood mononuclear cells(PBMNCs) were iso-
lated from heparinized blood samples of reanl cell carci-
noma patients by centrifugation over Ficoll-hypaque 
gradients. PBMNCs were washed three times and sus-
pended in RPMI-1640 medium. 
Assesment of natural killer (NK) and lymphokine acti-
vated killer (LAK)-like activities 
Fresh PBMNCs were placed in culture wells and cultured in 
nIFN- a at concentration of 4 X 102-4 X 104 IU/ml or rIFN-
'at concentration of 5 X 10 - 4 X 103 IU/ml . Cells were
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incubated for 48 hours at 37°C in a humidified atmosphere 
of 5% CO2 in air and were then washed three times in 
RPMI-1640 prior to the use. 
 Target cell lines used in this study included NK cell 
sensitive human myelogeneous leukemia cell line K562 cells 
and NK resistant human renal cell carsinoma cell line 
ACHN cells. These cell lines were maintained in suspension 
culutre in RPMI-1640 medium supplemented with 10% 
fetal calf serum. 
 NK and LAK-like activities were assayed by 18 hours" Cr 
release assay 15) against K562 and ACHN. Target cells were 
radiolabeled with 100 ,u Ci Na2 Cr04 at 37°C 1, hour. They 
were washed three times and finaly resuspended 1 X 10' cells 
/ml in complete medium." Cr-labeled target cells (5 X 103 
cells/0.05m1) were dispensed into the wells of 96-well V 
shaped bottomed microtiter plates, after which graded 
numbers of effector cells were added to give effector cells 
to target cell ratio (E:T ratio) of 50:1, 25:1, 12.5:1, and 
6.25: 1. Each assay was performed in triplicate. The plates 
were incubated for 18 hours at 37°C in a humidified atmos-
phere of 5% CO2 in air. After incubation, aliquots(100g1) 
of supernatant were removed from each well, and their 
radioactivity was determined in a r - counter (ARC-500, 
Aloca, Tokyo, Japan). The data were expressed as the 
percentage of" Cr release, and calculated according to 
following fomula: 
  cpm. experimental release-cpm. spontaneous release X 100 
  cpm. maximal release-cpm. spontaneous release 
Spontaneous release was the radioactivity release in 
supernatants from target ceells incubated in medium only, 
and maximal release was determined by counting an 
aliquot of resuspended target cells. 
 One lytic unit(LU) was defined as the number of 
effector cells required to lysis 20% of 5 X 103 target cells. 
The data are presented as LU/10' effector cells (Fig. 1). 
Cell sorting 
 Antibody in the Leu-series of Becton Dickinson 
Monoclonal Center Inc. (Mounntain View, CA), was used. 
For cell soarting FACScan and FACStar (Becton 
Dickinson) were used. As materials for cell soarting 
lymphocytes obtained from 400m1 of peripheral blood in 
the normal donors were used in various combinations with 
the antibody. We checked LAK-like activity of each 
subpopulation induced rIFN- r before and after sorting as 
follows: 
1) PBMNCs were sorted first and 24 hours later each 
subpopulation was set up to culture in rIFN- r at 500 IU/ 
ml for 24 hours at 37°C 5% CO2 in air. Cells were washed 
three times and LAK-like activity was assayed against 
ACHN by "Cr release assay. 
2) PBMNCs were cultured first in rIFN- r at 500 IU/ml for 
24 hours at 37'C, 5% CO2 in air and sorted. LAK-like
     Effector Target 
Patient's peripheral blood K562(NK senstive) 
     4, ACHN(NK resistant) 
PBMNCs were isolated by centrifugation 
over Ficoll-Hypaque gradients. 
Adherent celld removed after 1 h 37°C labeled with 51 Cr for 1 h 
incubaton on plastic dishes precoated 
supplemented with RPMI 1640 and IFN-a 
4x102-4x104lU/ml and IFN-y 5x10-4x103 
IU/ml. 
effector ells(1 x 107/ml) target cells(1 x 105/ml) 
             (Elf ratio 50:1,25:1,12.5:1,6.25:1) 
             standard18hs 51Crrelease assay 
                      cpm test - cpm medium
             %lysis= x 100 
                       cpm max. - cpm medium
Counts per minute(cpm) max. was determined by counting an aliquot 
of resuspe nded target cells; cpm medium was determined wells 
containing targets only with no effector added. All experiments were 
done in triplicate in V-shaped 96well microplates(Nuc.Denmark) 
1 LU was defined as the neumber of effector cells required to cause 
20% lysis of 5 x 103 targets. The data are presented as LU/107 
effector cells. 
         Fig.1 Experimental Method
activity was assayed against ACHN by "Cr release assay. 
Analysis of cytokines 
 Cytokines (IL-1 a, IL-1,6, IL-2, IL-6, IFN- a, IFN- r and 
TNF- a) in the serum of patients treated with nIFN- a and 
rIFN- r were analyzed. Serum samples were obtained 
patient before IFN therapy and 1, 2, 3weeks after IFN 
therapy. Cytokines were analyzed by sandwitch enzyme-
linked immunosorbent assay (ELISA) to detect the 
amount of the specific antigen.
RESULTS 
1) NK and LAK-like activities of PBMNCs in vitro in 9 
patients with renal cell carcinoma 
PBMNCs from patients with renal cell carcinoma were 
stimulated with nIFN- a or rIFN- r and tested in" Cr 
release assay against K562 and ACHN before administra-
tion of nIFN- a or rIFN- r. 
  Optimal concentration of nIFN- a or rIFN- r : As shown 
in Table 1, LAK-like activity increased after stimulation 
with nIFN- a or rIFN- r in all patients and the optimal 
concentration of nIFN- a or rIFN- r which induce maximal 
LAK-like activity differ in each patient. NK and LAK-like 
activities in patient were shown in Fig.2 and Fig.3.
Table 1 Concentration of IFN- a and IFN- r inducing the maximum LAK-like activity into lymphocytes in peripheral blood of 
the patinents before starting therapy with IFN-s 
  patient 1 2 3 4 5 6 7 8 9 
  IFN-a 4X103 2X103 1X103 4X103 2X103 4X103 4X103 2X103 4X103 
 (IU/ml) 
  IFN- r 5X 102 5X 102 1X103 5X 102 1X103 5X102 5X102 5X102 5X 102 
 (IU/ml)
Table 2 LAK-like activity of lymphocytes in peripheral blood 
of the patients withe renal cell carcinoma after induction 
assay for 48 hours at the optimal IFN concentration 
patient 1 2 3 4 5 6 7 8 9 
IFN-a 512 426 512 853 426 1137 320 320 320 
(20%LU) 
IFN- r 284 284 568 256 142 320 142 521 284 
(20%LU) 
IFN- a & r 1853 646 1024 1024 853 1706 568 1137 426 
(20%LU)
Fig.2 NK and LAK-like activities at various IFN- a concen-
tration in the induction assay for the patient with renal cell 
carcinoma (patient 1) 
 The optimal concentaration was 4 X 103 IU/ml.
Fig.3 NK and LAK-like activities at various IFN- r concen-
tration in the induction assay for the patient with renal cell 
carcinoma (patient 1) 
 The optimal concentaration was 5X 102 IU/ml.
 LAK-like activity induced by optimal concentration of 
nIFN- a or rIFN- 7 in patients: LAK-like activity induced 
by optimal concentration of nIFN- a or rIFN- r differ in 
patients(Table 2). The combination of nIFN- a and rIFN-
r induced LAK-like activity was not synergistic but 
additive. 
 The optimal kind of IFN: LAK-like activity induced by
nIFN- a was stronger than that by rIFN- 7 in patient 1, 2, 
4, 5, 6, 7 and 9. LAK-like activity induced by rIFN- r was 
stronger than that by nIFN- a in patient 3 and 8 (Table 2). 
This fact showed that the optimal kind of IFN differ in 
patients. 
2) NK and LAK-like activities in vivo of patient treated 
with nIFN- a and rIFN- r 
NK and LAK-like activities in vivo developed administra-
tion of nIFN- a. The activity was enhanced after addition 
of rIFN- 7 and returned after stopping administration of 
rIFN- r (Fig.4). 
3) Production of cytokines in the serum of patient treated 
with nIFN- a and rIFN- r 
We could not detect significant elevation of IL-1 a, IL-1,8, 
IL-2, IL-6, and TNF- a except administrated IFN- a and 
IFN- r. 
4) Subpopulation of lymphocytes obtained by cell sorting 
and their LAK-like activitiy 
We measured the LAK-like activity of each subpopulation 
of PBMNCs induced by rIFN- r. The strong LAK-like 
activity was seen in the fraction CD3(+)CD4( - ) ob-
tained by cell sorting after LAK induction assay(Fig.5). 
The strong LAK-like activity was also in the fraction CD 
3(+)CD4(-) obtained by LAK induction assay after cell 
sorting (Fig.6).
Table 3 Change of cytokine concentration with the passage of time under the combination therapy with IFN- a and IFN- r in the 
patient with renal cell carcinoma (patient 9)
                 1L-1 a IL-1,8 1L-2 1L-6 IFN- a IFN- r TNF- a 
            (pg/ml) (pg/ml) (pg/ml) (pg/ml) (pg/ml) (pg/ml) (pg/ml) 
pretreatment 10> 20> 121 20> 20> 20> 20> 
  1week 10> 20> 20> 20> 68 20> 20> 
  2week 10> 20> 20> 20> 70 20> 20> 
  3week 10> 20> 20> 20> 57 523 20>
Fig.6 LAK-like activity of cell sorted subpopulation after 
induction assay
Fig.4 Change of NK and LAK-like activities of the patient's 
PBMNCs under the combination therapy with IFN- a and IF 
N- r with passage of time (patient 9)
Fig.5 LAK-like activity of subpopulation cultured for 24 
hours in medium with and without IFN- 7500 IU/ml after cell 
sorting
DISCISSION 
 Renal cell carcinoma is comparatively rare in urological 
tumors, but the prognosis is not so good. The 5-year 
survival rate after nephrectomy is 55-65%. Death of cancer 
is noted frequently during the observation even in the
lower stage groups expected to have the favorable progno-
sis after surgical treatment. Nevertheless, no established 
treatment is available. The immunotherapy is said to be 
comparatively effective but the response rate is about 
20%. In recent several combination therapies of BRM have 
been tried. We have applied the nIFN- a and rIFN- r to 
patients with metastasis at first and recurrence. 
 PBMNCs are incubated with interferon in vitro and the 
killer cells which have broad spectrum are induced. Our 
results showed that there is an optimal concentration for 
individual patient to induce the maximal LAK-like 
acitvity in renal cell carcinoma-bearing patients. Further 
rIFN- 7 developed the higher cytotoxicity in comparison 
with nIFN- a in 2 patients, while nIFN- a induced the 
higher cytotoxicity in comparison with rIFN- 7 in other 
patients. This result suggests that there is an optimal kind 
of BRM suitable to each patient. Weigent et al 16) reported 
that the cytotoxicity in combination use of IFN- a and 
IFN- 7 was synergistic in vitro. However, it seems to be 
additive in our study. 
 We could not detect significant elevation of IL-1 a, IL-
1,8, IL-2, IL-6, and TNF- a levels in the serum of patients 
undergoing nIFN- a and rIFN- 7 therapy. Kubota 17) re-
vealed that PBMNCs from normal healthy donors acti-
vated with nIFN- a in vitro showed strong LAK-like 
activity, while no increase of cytokines other than nIFN-
a is noted in the supernatant of culture. Results of 
Kubota's experiment and this study suggest that cytotoxic
activity induced by IFN does not depend on other cytokines 
but IFN acts directly on the lymphocytes. Further, the 
strongest cytotoxicity induced by rIFN- r against ACHN 
was seen in the fraction CD3(+) CD4(-) either by the 
induction assay after cell sorting or by cell sorting after 
the induction assay. IFN- r seems to work directly on this 
fraction to induce LAK-like activity. Kubota " ) demon-
strated that IFN- a acted on the fraction CD3( - ) 
CD16(+) to induce LAK-like activity. The subpopulation 
of PBMNCs stimulated by IFN- r is different from 
subpopulation stimulated by IFN- a. This fact showed 
that combination therapy with IFN- a and IFN- r may be 
useful for the treatment of renal cell carcinoma.
CONCLUSION 
 The effect in combined use of IFN- a and IFN- r on renal 
cell carcinoma and action mechanisms were studied. 
(1) There seems to exist an optimal kind of BRM and an 
optimal concentration in each patient with renal cell 
carcinoma. 
(2) In vivo, the additive effect was noted on increased 
cytotoxic activity of PBMNCs of the patients with renal 
cell carcinoma upon combined use of IFN- a and IFN- r. 
(3) IFN- r seems to have induced the LAK-like activity to 
the fraction CD3(+)CD4(-) of lymphocytes in its action 
mechanism.
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